News

A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...

Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.

MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.

A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.

A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.

A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.

Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...

A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.

According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.